Asterand Logo Home Glossary Contact Us Online Ordering




Frozen & Fixed Tissues
RNA/DNA
Biofluids
Cell Lines
Tissue Microarrays
Human Primary Cells
Custom Procurement
Online Ordering

Human Breast Cancer Cell Lines

GryDiv

Through licensing agreements with the University of Michigan and the Karmanos Cancer Institute, Asterand provides 11 well characterized human breast cancer cell lines to assist in breast cancer research.

Ten SUM cell lines derived in Steve Ethier's lab while present at the University of Michigan are available for purchase. Each cell line, from a single patient, represents a different subtype of breast cancer. All of the currently known oncogenes with altered expression patterns in breast cancer, in various combinations, are represented and characterized in the SUM lines. These cell lines have been described in over 50 peer-reviewed publications, describing isolation and growth conditions, gene expression data through the use of Affymetrix GeneChips, and biomolecular markers, such as estrogen receptor and Her2 status. Click here to see a bibliography.

Asterand also offers the human breast cell line MCF10DCIS.com to researchers looking to model early breast cancer. MCF10DCIS.com is a clonal breast cancer cell line, derived by researchers in the Barbara Ann Karmanos Cancer Institute at Wayne State University. Pre-malignant MCF10AT cells were injected into severe combined immunodeficient (SCID) mice, resulting in tumor growth. The DCIS.com line was cloned from cell culture of this xenograft.

MCF10DCIS.com fulfills the need for models of early human breast disease such as DCIS, described by the National Institutes of Health Breast Cancer Progress Review Group, and can be useful for testing chemopreventive agents, screening for cancer-causing agents, and genetic analyses. Click here to see a bibliography.


44PE 52PE
102PT 149PT
1315MO2 159PT
185PE 190PT
225CWN 229PE


For product information sheet click here.

To purchase Cell lines online click here.


© 2008 Asterand plc. All rights reserved Terms of Use  GryDiv   E-Newsletter